Helena Smolak
Reporter, Real-Time EMEA News Desk at The Wall Street Journal
Journalist @WSJ chasing breaking news & hidden stories. Former Investigator @WFP @UN. Alumna @MediaLSE. For tips: [email protected]. Views my own.
Articles
-
5 days ago |
wsj.com | Helena Smolak
L’Oréal Chief Executive Nicolas Hieronimus said he expects another year of growth in sales and profitNicolas Hieronimus, chief executive of the French cosmetics company, said Thursday that the U.S. market turned out to be tougher than the company expected at the start of the year, while China–a source of weakness for the industry as of late–wasn’t as bad as anticipated. Europe was the top growth contributor for the group, Hieronimus said. Copyright ©2025 Dow Jones & Company, Inc.
-
6 days ago |
tradingview.com | Helena Smolak
L'Oreal 1Q Sales Rise as Europe Growth Offsets U.S. WeaknessUpdateSANL'Oreal posted higher first-quarter sales, boosted by demand for its high-end fragrances and makeup in Europe that offset weakness in the U.S. before President Trump unveiled his sweeping tariffs.
-
1 week ago |
wsj.com | Helena Smolak
L’Oreal posted higher sales for the first quarter, boosted by its luxury products division even as the sector faces an uncertain environment due to waning demand. The French cosmetics giant on Thursday reported sales of 11.47 billion euros ($13.08 billion) for the three months to the end of March, up 4.4% on-year and 3.5% on a like-for-like basis. The figure came in line with analysts’ forecasts of €11.47 billion, according to a Visible Alpha consensus.
-
1 week ago |
marketscreener.com | Helena Smolak
By Helena Smolak L'Oreal posted higher sales for the first quarter boosted by its luxury products division even as the sector faces an uncertain environment due to waning demand. The French cosmetics giant on Thursday reported sales of 11.47 billion euros ($13.08 billion) for the three months to the end of March, up 4.4% on-year and 3.5% on a like-for-like basis. The figure came in line with analysts' forecasts of 11.47 billion euros, according to a Visible Alpha consensus.
-
1 week ago |
ca.marketscreener.com | Helena Smolak
By Helena Smolak GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology portfolio. GSK said Thursday that the approval for Blenrep is in combination with other drugs to treat multiple myeloma in patients whose first treatment didn't work or who had severe side effects.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 85
- Tweets
- 78
- DMs Open
- No
I spoke with @Novartis 's CEO about why his appetite for obesity deals isn't over yet - and how the Swiss pharma giant plans to bridge its pipeline gap between 2027 to 2030.
Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s https://t.co/Xrg7IxdeIF
Pharma's bet on #AI to advance drug development seems promising but there are hurdles and the biggest aren't even technological. Technology is not the primary bottleneck preventing faster progress; it’s largely operational and cultural challenges. My latest analysis:
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles https://t.co/0RinbBqGhH
#JPM25 is around the corner - I recently spoke about the end of a weight loss drugs shortage in the U.S. and what that means for compounders: https://t.co/ZcwJjumPzc